Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children410.24287/1726-1708-2017-16-4-21-26СтатьиChanges in CD19 expression after blinatumomab treatment in pediatric patients with relapsed/refractory B-lineage acute lymphoblastic leukemiaИзменение экспрессии CD19 опухолевыми клетками при применении блинатумомаба у детей с рецидивами и рефрактерным течением В-линейного острого лимфобластного лейкозаhttps://orcid.org/0000-0003-2921-9770GluhanyukE. V.ГлуханюкЕ.В.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

IllarionovaO. I.ИлларионоваО.И.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

KashporS. A.КашпорС.А.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

PlyasunovaS. A.ПлясуноваС.А.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

https://orcid.org/0000-0002-4779-1896MiakovaN. V.МяковаН.В.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

https://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА. А.
Russian Federation

Russia 117997, Moscow, Samory Mashela st., 1

https://orcid.org/0000-0002-0889-6986PopovA. M.ПоповА.М.
Russian Federation

MD, PhD, Head of Cell immunology and immunogenesis laboratory

Russia 117997, Moscow, Samory Mashela st., 1

+7 (495) 287-6570

uralcytometry@gmail.comDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России09112017164212609082018Copyright ©; 2017, «D. Rogachev NMRCPHOI»Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2017«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/4

Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct targeting CD3 and CD19, resulting in T-cell-mediated lysis of malignant B cells. CD19 downexpression is shown to be one of the possible mechanisms of tumor cells adaptation and subsequent escape from treatment. The aim of the present study was to evaluate changes of CD19 expression on residual tumor cells in children with BCP-ALL treated with blinatumomab. 39 patients with relapsed/refractory BCP-ALL who completed at least one course of blinatumomab, were studied. MRD monitoring was performed by 8-color flow cytometry. In those children, who didn’t respond and/or developed subsequent relapse, CD19 downexpression seems to be one of the significant pathways for tumor escape from blinatumomab – 50% of relapses were CD19-negative, and in 26.3% of all relapsed/resistant cases CD19-negative blasts were detected at least on MRD level. Rather frequent loss of CD19 could be a serious obstacle for flow cytometric MRD monitoring, but application of expanded antibodies panel and use of 10–12-color investigation allows residual blasts detection in nearly all cases.

acute lymphoblastic leukemiablinatumomabCD19minimal residual diseaseострый лимфобластный лейкозблинатумомабCD19минимальная остаточная болезньZugmaier G., Klinger M., Schmidt M., Subklewe M. Клинический обзор анти-CD19 BiTE® и ex vivo данных об анти-CD33 BiTE ® в качестве примеров ретаргетирования Т-клеток при гематологических опухолях. 2016; 67: 58-66.Kantarjian H.M., Stein A.S., Bargou R.C., et al. Blinatumomab Treatment of Older Adults With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leuke-mia: Results From 2 Phase 2 Studies. Cancer 2016; 122 (14): 2178-85.Stackelberg A. Von., Locatelli F., Zugmaier G., et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 2016; 34 (36): 4381-9.Ruella M., Maus M.V. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J 2016; 14: 357-62.Cherian S., Miller V., McCullouch V., Fromm J.R., et al. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytom Part B Clin Cytom 2016.Попов А.М., Белевцев М.В., Боякова Е.В., Вержбицкая Т.Ю., Мовчан Л.В., Фадеева М.С. Стандартизация определения минимальной остаточной болезни методом проточной цитометрии у детей с В-линейным острым лимфобластным лейкозом. Опыт работы российско- белорусской кооперативной группы. Онкогематология 2016; 11: 64-73.Dworzak M.N., Gaipa G., Ratei R., et al. Standardization of Flow Cytometric Minimal Residual Disease Evaluation in Acute Lymphoblastic Leukemia : Multicentric Assessment Is Feasible. Cytom Part B (Clinical Cytom) 2008; 340: 331-40.Dworzak M.N., Gaipa G., Ratei R., et al. Standardization of Flow Cytometric Minimal Residual Disease Evaluation in Acute Lymphoblastic Leukemia : Multicentric Assessment Is Feasible. Cytom Part B (Clinical Cytom) 2008; 340: 331-40.Haddox C.L., Mangaonkar A.A., Chen D., Shi M., He R. Blinatumomab-induced lineage switch of B-ALL with t(4 ; 11) (q21 ; q23) KMT2A/AFF1 into an aggressive AML : pre- and post-switch phenotypic , cytogenetic and molecular analysis. Blood Cancer J 2017.Haddox C.L., Mangaonkar A.A., Chen D., Shi M., He R. Blinatumomab-induced lineage switch of B-ALL with t(4 ; 11) (q21 ; q23) KMT2A/AFF1 into an aggressive AML : pre- and post-switch phenotypic , cytogenetic and molecular analysis. Blood Cancer J 2017.Winters A.C., Bernt K.M. MLL-Rearranged Leukemias - An Update on Science and Clinical Approaches. Front Pediatr 2017; 5: 11-3.Weiland J., Pal D., Case M., et al. BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Leukemia 2016; 30 (9): 1920-3.Fischer J., Paret C., Malki E., et al. CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis 2017; 40 (5): 187-95.Braig F., Brandt A., Goebeler M., et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 2016.Duell J., Dittrich M., Bedke T., et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 2017; (September 2016): 1-10.Nägele V., Kratzer A., Zugmaier G., et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol 2017; 6 (1): 14.Zugmaier G., Gukbuget N., Klinger M., et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 2015; 126 (24): 2578-84.Rayes A., Mcmasters R.L., O’Brien M.M. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy. Pediatr Blood Cancer 2016; 63 (6): 1113-5.Gardner R., Wu D., Cherian S., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016; 127 (20): 2406-10.Jacoby E., Nguyen S.M., Fountaine T.J., et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Com-mun 2016; 7: 12320.De Zen L., Bicciato S., Kronnie G., Basso G. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification 2003; (October 2002): 1557-65.